Supreme Court Ruling to Uphold ACA
This decision adds certainty to related health insurance programs.
In a 7-2 decision, the U.S. Supreme Court voted to uphold the Affordable Care Act. This was largely expected by us and, in our opinion, the rest of the market. This time around, the court ruled that the complaining parties were not sufficiently harmed by the ACA's individual mandate, which was reduced to $0 by the Republican-controlled Congress as part of tax legislation in 2017. Because this court's ruling (or one based on the severability of the individual mandate from the rest of the ACA) was largely expected by us, we are making no changes to our moat ratings or fair value estimates for the narrow-moat health insurers we cover: Anthem (ANTM) , Centene (CNC) , Cigna (CI) , CVS (CVS), Humana (HUM), and UnitedHealth (UNH). However, the ruling does add some certainty around this law that touches so many parts of the U.S. healthcare system.
Most important, this ruling means that ACA-related programs, such as the individual exchanges and ongoing expansion of Medicaid, will continue. As the leading Medicaid managed-care organization and provider of plans on the individual exchanges, Centene would have been most affected by a ruling that eliminated those ACA programs. Instead, this ruling clears the way for efforts to increase the insurance rolls in the U.S., which are largely based on these ACA programs. For example, the American Rescue Plan Act of 2021 temporarily extended tax credits to cap the amount of household income that could be spent on the individual exchanges to 8.5% for all individuals (not just those who made up to 400% of the federal poverty level, which was initially part of the ACA). That improved affordability is attracting new individuals to the exchanges during the ongoing sign-up period. Similarly, in the American Rescue Plan Act, carrots were extended to nonexpansion states to expand their Medicaid populations through ACA-related initiatives. Through another budget reconciliation bill that will likely be brought to Congress this fall, these initiatives could be extended permanently.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Julie Utterback does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.